Meanwhile, the BSE Sensex was up 137.97 points or 0.84% to 16,617.55.

On BSE, 1.22 lakh shares were traded in the counter as against average daily volume of 41,280 shares in the past one quarter.

The stock hit a high of Rs 359.50 so far during the day, which is a 52-week high for the counter. The stock hit a low of Rs 342 so far during the day. The stock had hit a 52-week low of Rs 262.70 on 11 May 2011.

The stock had outperformed the market over the past one month till 9 May 2012, rising 10.02% compared with the Sensex's 4.31% fall. The scrip had also outperformed the market in past one quarter, surging 13.8% as against Sensex's 7.58% fall.

The company has an equity capital of Rs 27.05 crore. Face value per share is Re 1.

The Glenmark Pharmaceuticals stock has rallied 8.47% in two trading sessions from Rs 329.75 on Tuesday, 8 May 2012, after the company after market hours on 8 May 2012 reported strong Q4 earnings. The stock had risen 3.03% to settle at Rs 339.75 on Wednesday, 9 May 2012.

Glenmark Pharmaceuticals' consolidated net profit rose 32.5% to Rs 150.36 crore on 34.1% growth in net sales to Rs 1065.86 crore in Q4 March 2012 over Q4 March 2011. Consolidated net profit rose 1.6% to Rs 460.35 crore on 36.3% growth in net sales to Rs 4020.64 crore in the year ended 31 March 2012 over the year ended 31 March 2011.

Glenmark Pharmaceuticals (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai. It is a leading player in the discovery of new molecules, both NCEs (new chemical entity) and NBEs (new biological entity). The company has a significant presence in branded generics markets across emerging economies including India. GPL along with its subsidiary has twelve manufacturing facilities in four countries and has five R&D centres. Its subsidiary, Glenmark Generics services the requirements of the US and the Western Europe Generics business. The API business sells its products in approximately 80 countries, including the US, various countries in the EU, South America and India.